BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share of ...
Please provide your email address to receive an email when new articles are posted on . GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol ...
The studies examined the efficacy of Symbicort pressurized metered dose inhaler (pMDI) 160/4.5mcg vs. formoterol 4.5mcg in reducing COPD exacerbations in adults with moderate to severe COPD. The FDA ...
(RTTNews) - The U.S. Food and Drug Administration approved Mylan Pharmaceuticals, Inc.'s generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. It is the first FDA- ...
"COPD is a serious, debilitating lung disease affecting 12 million Americans, (1)" said lead investigator Dr. Donald Tashkin of the University of California, Los Angeles (UCLA). "If SYMBICORT receives ...
US regulators have given the green light to AstraZeneca's blockbuster Symbicort to be marketed for chronic obstructive pulmonary disease. US regulators have given the green light to AstraZeneca’s ...
The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...
Please provide your email address to receive an email when new articles are posted on . The FDA announced approval of the first generic of Symbicort — budesonide and formoterol fumarate dihydrate — ...
Full approval by the FDA follows tentative approval for the complex drug delivery advice for asthma and chronic obstructive pulmonary disease (COPD) granted by the FDA last week amid a patent dispute.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results